Introduction
Pancost DSR by Astemax Biotech is a prolonged-release capsule featuring pantoprazole gastro-resistant pellets combined with domperidone sustained-release pellets, delivering extended acid suppression and motility enhancement. This advanced formula ensures consistent efficacy for managing GERD and indigestion, backed by high-quality WHO-GMP certified manufacturing.
Product Overview
Pancost DSR contains pantoprazole 40 mg (gastro-resistant) and domperidone 30 mg (prolonged-release), designed for once-daily dosing. The prolonged formula protects pantoprazole from stomach acid, releasing it in the intestine for optimal proton pump inhibition. Domperidone’s sustained action improves gastric emptying, reducing reflux symptoms effectively over 24 hours.
Key Benefits
-
Treats GERD, erosive esophagitis, gastric ulcers, and nausea with prolonged relief.
-
Pantoprazole blocks acid production at the source; domperidone enhances gut motility for faster symptom control.
-
High patient compliance due to single-dose convenience and minimal side effects.
Quality Assurance
Manufactured by Astemax Biotech in WHO-GMP certified facilities, Pancost DSR adheres to global standards for purity, stability, and bioavailability. Rigorous testing ensures batch-to-batch consistency, making it a reliable choice for ethical prescribing.
Mechanism of Action
Pantoprazole inhibits the H+/K+ ATPase enzyme in parietal cells, reducing acid secretion by up to 95%. Domperidone acts as a dopamine antagonist, promoting peristalsis without crossing the blood-brain barrier significantly. The dual prolonged-release technology provides steady therapeutic levels for superior efficiency
